- Home
- FNLC vs ACIU Comparison
FNLC vs ACIU Comparison
Compare FNLC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- ACIU
- Stock Information
- Founded
- FNLC 1864
- ACIU 2003
- Country
- FNLC United States
- ACIU Switzerland
- Employees
- FNLC N/A
- ACIU N/A
- Industry
- FNLC Major Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- ACIU Health Care
- Exchange
- FNLC Nasdaq
- ACIU Nasdaq
- Market Cap
- FNLC 295.4M
- ACIU 332.4M
- IPO Year
- FNLC 1999
- ACIU 2016
- Fundamental
- Price
- FNLC $26.77
- ACIU $2.68
- Analyst Decision
- FNLC
- ACIU Strong Buy
- Analyst Count
- FNLC 0
- ACIU 2
- Target Price
- FNLC N/A
- ACIU $12.00
- AVG Volume (30 Days)
- FNLC 17.6K
- ACIU 134.5K
- Earning Date
- FNLC 01-22-2025
- ACIU 11-05-2024
- Dividend Yield
- FNLC 5.20%
- ACIU N/A
- EPS Growth
- FNLC N/A
- ACIU N/A
- EPS
- FNLC 2.38
- ACIU N/A
- Revenue
- FNLC $78,192,000.00
- ACIU $48,505,404.00
- Revenue This Year
- FNLC N/A
- ACIU $85.33
- Revenue Next Year
- FNLC N/A
- ACIU $80.69
- P/E Ratio
- FNLC $11.64
- ACIU N/A
- Revenue Growth
- FNLC N/A
- ACIU 4097200.00
- 52 Week Low
- FNLC $21.77
- ACIU $2.25
- 52 Week High
- FNLC $31.05
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- FNLC 31.37
- ACIU 27.49
- Support Level
- FNLC $26.12
- ACIU $2.62
- Resistance Level
- FNLC $28.16
- ACIU $3.02
- Average True Range (ATR)
- FNLC 0.65
- ACIU 0.13
- MACD
- FNLC -0.35
- ACIU -0.05
- Stochastic Oscillator
- FNLC 0.00
- ACIU 9.52
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.